|Mr. James R. Sapirstein R.Ph., M.B.A.||Pres, CEO & Chairman||622k||N/A||1961|
|Mr. Daniel H. Schneiderman||Chief Financial Officer||356.03k||N/A||1978|
|Dr. James E. Pennington||Chief Medical Officer||324.8k||N/A||1943|
|Mr. Martin Krusin M.B.A.||Sr. VP of Corp. Devel.||N/A||N/A||N/A|
AzurRx BioPharma, Inc., a clinical stage biopharmaceutical company, focuses on the development of recombinant proteins for the treatment of gastrointestinal diseases. Its therapeutic products administer patients as oral non-systemic biologics. The company's lead therapeutic is MS1819, a recombinant lipase for the treatment of exocrine pancreatic insufficiency. It is also developing two clinical programs using proprietary formulations of niclosamide, a pro-inflammatory pathway inhibitor, including FW-420, for grade 1 Immune Checkpoint Inhibitor-associated colitis and diarrhea in oncology patients; and FW-1022, for COVID-19 gastrointestinal infections. AzurRx BioPharma, Inc. has a license agreement with First Wave Bio, Inc. The company was incorporated in 2014 and is headquartered in Delray Beach, Florida.
AzurRx BioPharma, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.